共 217 条
[1]
Wang L(2014)Tuberculosis prevalence in China, 1990-2010; a longitudinal analysis of national survey data Lancet 383 2057-2064
[2]
Zhang H(2015)Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines Clin Infect Dis 61Suppl 3 S102-S118
[3]
Ruan Y(2010)Antituberculosis drugs: drug interactions, adverse effects, and use in special situations-part 1: first-line drugs J Bras Pneumol 36 626-640
[4]
Chin DP(1995)A model of isoniazid-induced hepatotoxicity in rabbits J Pharmacol Toxicol Methods 34 109-116
[5]
Xia Y(2004)Nitric oxide generated from isoniazid activation by KatG: source of nitric oxide and activity against mycobacterium tuberculosis Antimicrob Agents Chemother 48 3006-3009
[6]
Cheng S(2009)An Oxyferrous Heme/protein-based radical intermediate is catalytically competent in the catalase reaction of mycobacterium tuberculosis catalase-peroxidase (KatG) J Biol Chem 284 7017-7029
[7]
Chen M(2016)Executive summary: official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis Clin Infect Dis 63 181-1352
[8]
Zhao Y(1976)Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis Ann Intern Med 84 1340-684
[9]
Jiang S(2015)Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study Gastroenterology 148 682-1751
[10]
Du X(2015)A rare case of isoniazid-induced erythroderma Indian J Pharmacol 47 1742-1549